IP that matters: behind Orexo’s patent win against generic giant (NLS Days)

IP that matters: behind Orexo’s patent win against generic giant (NLS Days)
date
October 13, 2025
TIme
16:30 - 17:30 CEST
Address

Flow Stage, Svenska Mässan, Gothenburg

When a challenger comes for your life’s work, how do you fight back and win?

At Nordic Life Science Days, you’ll get a rare inside look at Orexo’s decisive US patent litigation victory over Sun Pharma, a case that proves the power of a rock-solid IP strategy in protecting both innovation and patient impact. 

Hear from those who lived it: 

  • Orexo – on the effective use of IP to meet its business objectives, safeguarding lifechanging treatments for opioid dependence; 
  • Steptoe -  US litigators who brought and successfully argued the case before the court; and
  • Potter Clarkson – Orexo’s patent attorneys who had a key, central role in preparing the ground for that success

Join us on the Flow Stage at 16:30, Monday 13 October for an insightful session.

Because when innovation is under fire, strategy is everything. 

Latest News

Fake weight-loss medications and new enforcement possibilities

Fake weight-loss medications and new enforcement possibilities

CJEU rules on hosting defence for EU platforms

CJEU rules on hosting defence for EU platforms

Potter Clarkson ranked in Managing IP's IP STARS 2026

Potter Clarkson ranked in Managing IP's IP STARS 2026

Combination therapies: IP considerations for synergistic biologic products

Combination therapies: IP considerations for synergistic biologic products

Perfect storm - four drivers behind the mRNA litigation wave

Perfect storm - four drivers behind the mRNA litigation wave

Patent landscape and freedom-to-operate analysis for RNA-based therapies: identifying IP risks early

Patent landscape and freedom-to-operate analysis for RNA-based therapies: identifying IP risks early

Kodak v FujiFilm: the Court of Appeal confirms UPC’s long-arm jurisdiction

Kodak v FujiFilm: the Court of Appeal confirms UPC’s long-arm jurisdiction

Comparing EPC Article 53(a) and US patent law in gene editing ethics

Comparing EPC Article 53(a) and US patent law in gene editing ethics

See All News